A recent Modern Healthcare Executive report takes a look at the seven most out-of-reach drugs as a result of their high costs.
Biologics, according to West Monroe Partners Senior Director and Leader of Life Sciences Ed Francis tells MHE says while biologic prices will come down, they ultimately remain high.
“The high-cost prescriptions today tend to exist for biologic drugs,” he said. “Ultimately, the costs will come down as patents expire and biosimilars come into the market.”
Drugs used to treat rare diseases also rack up significant bills.
“The 39 most expensive drugs in the U.S. range from an annual cost of low $10,000s to high $500,000,” VUE Software Vice President of Strategy John Sarich says. “They are designed to treat very serious medical conditions.
“It should be noted that pharmaceutical companies are international businesses with drug manufacturers spread throughout the world,” he added. “While subsidies abound, the U.S. does, in fact, pick up a disproportionate share of the drug costs.”
To read more, click here.
